DNLI supply chain intelligence for Denali Therapeutics Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ROYALTY-PHARMA-INVESTMENTS-2023-ICAV | ROYALTY-PHARMA-INVESTMENTS-2023-ICAV | 92% | The Company accounts for the synthetic royalty funding agreement with Royalty Pharma Investments 2023 ICAV ("Royalty Pharma") pursuant to which Royalty Pharma agreed to provide up to $ 275.0 million … |
| RPRX | Royalty Pharma plc | 90% | The information contained in Item 1.01 of the Form 8-K filed by Denali Therapeutics Inc. (the “Company”) on December 4, 2025 related to the synthetic royalty funding agreement between the Company and… |
| RPRX | Royalty Pharma plc | 90% | Reciprocal relationship from RPRX graph: Reciprocal relationship from DNLI graph: The information contained in Item 1.01 of the Form 8-K filed by Denali Therapeutics Inc. (the “Company”) on December … |
| BIOGEN | BIOGEN | 80% | We have numerous arrangements with biopharmaceutical companies, technology companies, academic institutions, foundations, and patient-focused data companies. Notable active arrangements include those… |
| TAKEDA | TAKEDA | 80% | We have numerous arrangements with biopharmaceutical companies, technology companies, academic institutions, foundations, and patient-focused data companies. Notable active arrangements include those… |
| IKT | Inhibikase Therapeutics, Inc. | 72% | Reciprocal relationship from IKT graph: tractive; and • a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; if a product candidate obta… |
| RGNX | REGENXBIO Inc. | 72% | Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that … |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from DNLI graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from DNLI graph: entual commercialization of one o… |
| SNYNF | Sanofi | 72% | entual commercialization of one or more of our product candidates. We expect to continue to incur significant expenses and operating losses as we advance our current clinical stage programs through h… |
| SANOFI | SANOFI | 70% | We hold significant development and commercialization rights to all of our CNS programs, including the programs which are subject to our collaboration agreements with Biogen and Takeda, where we shar… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| TAKEDA-PHARMACEUTICAL-COMPANY-LIMITED | TAKEDA-PHARMACEUTICAL-COMPANY-LIMITED | 90% | The opt-in by Takeda on the PTV:PGRN and ATV:TREM2 programs represented two new contracts with a customer for accounting purposes |
| TKPHF | Takeda Pharmaceutical Company Limited | 90% | Reciprocal relationship from TKPHF graph: Reciprocal relationship from DNLI graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from DNLI graph: The opt-in by Takeda on the PTV:P… |
| BIOGEN | BIOGEN | 85% | we fund our operations primarily with the proceeds from the sale of common stock and payments received from our collaboration partners, including those received under agreements with Takeda, Sanofi, … |
| SANOFI | SANOFI | 85% | we fund our operations primarily with the proceeds from the sale of common stock and payments received from our collaboration partners, including those received under agreements with Takeda, Sanofi, … |
| IKT | Inhibikase Therapeutics, Inc. | 72% | Reciprocal relationship from IKT graph: Reciprocal relationship from DNLI graph: Reciprocal relationship from IKT graph: tractive; and • a product candidate may not be capable of being produced in co… |
| RGNX | REGENXBIO Inc. | 72% | Reciprocal relationship from RGNX graph: Reciprocal relationship from DNLI graph: Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from DNLI graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from DNLI graph: Reciprocal relationship from SNYN… |
| SNYNF | Sanofi | 72% | V:PGRN Technology License performance obligation delivered in the collaboration agreement. Since ASC 808 does not address recognition and measurement, the Company looked to other accounting literatur… |
| F-STAR-BIOTECHNOLOGY-LIMITED | F-STAR-BIOTECHNOLOGY-LIMITED | 62% | e, high credit quality institutions. All marketable securities with unrealized losses as of each balance sheet date had been in a loss position for less than twelve months or the loss is not material… |
| F-STAR-GAMMA-LIMITED | F-STAR-GAMMA-LIMITED | 62% | e, high credit quality institutions. All marketable securities with unrealized losses as of each balance sheet date had been in a loss position for less than twelve months or the loss is not material… |
| F-STAR-LTD | F-STAR-LTD | 62% | e, high credit quality institutions. All marketable securities with unrealized losses as of each balance sheet date had been in a loss position for less than twelve months or the loss is not material… |
| LONZA-SALES-AG | LONZA-SALES-AG | 62% | not generated any product revenue. We do not expect to generate any product revenue unless and until we obtain regulatory approval of and commercialize any of our product candidates, and we do not kn… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| DNLI-DEBT | Debt stack $40.0M | 90% | Market cache reports total debt of $40.0M. |
| DNLI-DEBT-9105 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2017-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| DNLI-OWNER-BLACKROCK-INC | BlackRock, Inc. | 90% | 13F overlay lists BlackRock, Inc. as top holder; 272 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| WHWK | Whitehawk Therapeutics, Inc. | 100.00 | 2 | |
| PSNL | Personalis, Inc. | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 |